Medigen and the University of Louisville (UofL) present collaborative research on V5040 chikungunya vaccine at the Annual meeting of the American Society for Virology in Columbus, OH. Scientists showed that novel vaccine developed by Medigen and UofL is safe, highly immunogenic, and protects C56BL/6J mice from experimental challenge with infectious chikungunya virus. Chikungunya virus [...]
June 21-24, 2024. Medigen and the University of Louisville (UofL) present collaborative research on V5040 chikungunya vaccine at the Annual meeting of the American Society for Virology in Columbus, OH. Scientists showed that novel vaccine developed by Medigen and UofL is safe, highly immunogenic, and protects C56BL/6J mice from experimental challenge with infectious chikungunya virus. [...]
Medigen, Inc. is adding another 6,000 SF to its 6,000 SF facility to expand operations in Frederick, MD
Medigen, Inc. (Frederick. MD) receives U.S. patent “Vaccines against infectious diseases caused by positive stranded RNA viruses”. This patent will provide freedom of operations to Medigen to develop multiple vaccines based on its proprietary iDNA platform including vaccines for alphaviruses and flaviviruses.
Policy Statement As a professional research corporation, Medigen, Inc. is committed to protecting the integrity and objectivity of its research activities by ensuring that the design, conduct, and reporting of research will not be biased or appear to be biased by a personal financial conflict of interest. Medigen, Inc. has implemented this policy to identify, [...]
January 29, 2019. Medigen presented experimental vaccines for two life-threatening emerging viruses at the 2019 ASM Biothreats conference in Washington, DC. Venezuelan Equine Encephalitis (VEE) virus is a mosquito-borne alphavirus that causes periodic disease outbreaks in North, Central, and South Americas including the U.S. Medigen’s VEE vaccine V4020 showed production of virus-neutralizing antibodies and [...]
